NewAmsterdam Pharma Company N.V. Stock Börse Stuttgart
Stocks
KH6
NL00150012L7
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
15:52:44 24/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 19.88 EUR | +0.20% |
|
+7.44% | -32.50% |
| 08-26 | NewAmsterdam Pharma Presents Data From Obicetrapib Development Program At European Society Of Cardiology Congress 2026 | CI |
| 08-14 | Newamsterdam Pharma Company N.V. Announces Executive Changes | CI |
| Market Cap | 2.38B 2.71B 2.24B 2.05B 3.82B 260B 3.85B 26.87B 10.42B 132B 10.18B 9.96B 429B | P/E 2026 * |
-12.1x | P/E 2027 * | -12.9x |
|---|---|---|---|---|---|
| Enterprise Value | 1.96B 2.23B 1.84B 1.68B 3.14B 213B 3.16B 22.08B 8.56B 109B 8.37B 8.18B 353B | EV / Sales 2026 * |
79.4x | EV / Sales 2027 * | 15.3x |
| Free-Float |
99.1% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| NAMS | End-of-day quote | |
Nasdaq
| NAMS | Delayed | |
|
CBOE
| NAMS | Real-time | |
|
Tradegate
| KH6 | Real-time | |
|
Deutsche Boerse AG
| KH6 | Delayed | |
|
Börse Stuttgart
| KH6 | Delayed | |
|
Boerse Muenchen
| KH6 | Real-time |
Last Transcript: NewAmsterdam Pharma Company N.V.
| 1 week | +7.44% | ||
| Current month | -8.67% | ||
| 1 month | -16.69% | ||
| 3 months | -27.65% | ||
| 6 months | -23.08% | ||
| Current year | -32.50% |
| 1 week | 18.18 |  | 20.81 |
| 1 month | 18.18 | | 23.98 |
| 3 years | 5.45 | | 35.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Davidson
CEO | Chief Executive Officer | 69 | 01/11/2022 |
Mayur Somaiya
DFI | Director of Finance/CFO | 52 | 23/10/2023 |
John Kastelein
CTO | Chief Tech/Sci/R&D Officer | 72 | 01/11/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Davidson
BRD | Director/Board Member | 69 | 01/11/2022 |
John Kastelein
BRD | Director/Board Member | 72 | 01/11/2022 |
James Topper
BRD | Director/Board Member | 64 | 01/11/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.20% | +7.44% | -14.46% | +119.28% | 2.71B | |
| +0.06% | +6.49% | +60.29% | +111.13% | 74.18B | |
| -0.12% | -3.80% | +34.24% | +74.98% | 59.55B | |
| -2.05% | -3.46% | -18.60% | +352.20% | 25.84B | |
| -2.39% | +2.74% | +0.19% | -5.91% | 24.73B | |
| -0.74% | +1.47% | +21.93% | -9.68% | 20.87B | |
| +1.29% | -2.49% | +152.11% | +333.06% | 15.32B | |
| -2.44% | -0.09% | +42.50% | +164.11% | 14.06B | |
| -3.91% | -4.91% | -14.10% | +779.68% | 13.12B | |
| -1.12% | -3.04% | +15.72% | +234.56% | 11.85B | |
| Average | -1.27% | -0.40% | +27.98% | +215.34% | 28.84B | |
| Weighted average by Cap. | -0.80% | +0.70% | +35.78% | +160.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 24.64M 28.07M 23.16M 21.18M 39.57M 2.69B 39.86M 278M 108M 1.37B 105M 103M 4.45B | 119M 136M 112M 102M 191M 13B 193M 1.35B 521M 6.63B 510M 499M 21.49B |
| Net income | -202M -230M -190M -173M -324M -22.01B -326M -2.28B -883M -11.22B -863M -844M -36.39B | -196M -224M -184M -169M -315M -21.42B -318M -2.22B -859M -10.92B -840M -821M -35.41B |
| Net Debt | -424M -483M -398M -364M -680M -46.24B -685M -4.78B -1.85B -23.57B -1.81B -1.77B -76.43B | -556M -634M -523M -478M -894M -60.72B -900M -6.28B -2.44B -30.96B -2.38B -2.33B -100B |
| Date | Price | Change |
|---|---|---|
| 24/09/26 | €19.59 | -1.28% |
| 23/09/26 | €19.85 | -2.86% |
| 22/09/26 | €20.43 | +4.37% |
| 21/09/26 | €19.58 | +0.57% |
| 18/09/26 | €19.47 | +2.10% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NAMS Stock
- KH6 Stock
Select your edition
All financial news and data tailored to specific country editions
